Clinical Trial Update: Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a conditioning regimen of carmustine, etoposide, cytarabine, melphalan, and alemtuzumab followed by donor stem cell transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Alkeran (melphalan)
• Ara-C (cytarabine)
• BiCNU (carmustine)
• CAMPATH (ALEMTUZUMAB)
• Toposar (Etoposide)

Snippet

Sponsor: Cancer Research UK | Conditions: Lymphoma | Phase 2 | Status: UNKNOWN